8-K: Picard Medical Secures $500K Convertible Note Financing

Sentiment:

Material Definitive Agreement 13 April 2026 4:15 PM

Picard Medical, Inc. has entered into a securities purchase agreement for a $555,555.56 convertible promissory note with Quick Capital, LLC, receiving $490,000 in funding.

Capital raisePicard Medical, Inc. entered into a Securities Purchase Agreement with Quick Capital, LLC for the issuance and sale of a convertible promissory note in the principal face amount of $555,555.56.The company received $490,000.00 in cash consideration at closing, after accounting for an original issue discount of $55,555.56 and $10,000.00 withheld for the Buyer's due diligence fees.Additionally, 80,128 shares of the Company's common stock were issued as origination shares.

Worse than expectedThe financing involves a significant original issue discount and a substantial one-time interest charge, reducing the effective capital received.The default provisions are highly punitive, with repayment escalating to 150%-200% of outstanding amounts.The conversion price is set at a deep discount (75% of the lowest trading price), indicating a high likelihood of future dilution for existing shareholders.The company faces numerous potential 'Events of Default' that could trigger severe financial consequences.

Summary

Picard Medical, Inc. has secured a convertible promissory note with a face value of $555,555.56 from Quick Capital, LLC.
The company received $490,000 in cash at closing, after accounting for a $55,555.56 original issue discount and $10,000 for the buyer's due diligence fees.
The note includes a one-time interest charge of $66,666.67, representing 12% of the principal.
The note matures in nine months and is to be repaid in six equal monthly installments starting July 1, 2026.
Upon an Event of Default, the note accrues interest at 20% or the maximum legal rate, and the principal becomes immediately due and payable at 150% of the outstanding amount, capped at 200%.
The buyer also received 80,128 shares of common stock as origination shares.
The buyer has the right to convert the note into common stock at 75% of the lowest trading price over the preceding 10 trading days, subject to a 4.99% beneficial ownership limitation.
The issuance is made under exemptions from registration under the Securities Act of 1933.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a negative development due to the high cost of capital, significant discount, punitive default terms, and potential for substantial future dilution.

Positives

Secured $490,000 in immediate funding.
Received additional consideration in the form of 80,128 origination shares.
The convertible note offers flexibility for conversion into equity under certain conditions.
The financing agreement includes standard representations and warranties, providing a level of assurance.
The company has reserved sufficient shares for potential conversion.
The note includes provisions for prepayment at a discount within the first 90 days.

Negatives

The note carries a significant original issue discount of $55,555.56.
A substantial one-time interest charge of $66,666.67 is applied.
Upon default, the repayment amount escalates to 150%-200% of the outstanding principal and interest.
The conversion price is set at a discount (75% of the lowest trading price), indicating potential future dilution.
The company is subject to restrictive covenants, including limitations on dividends, stock repurchases, and asset sales without the buyer's consent.
The note is cross-defaulted with other agreements, increasing risk.
Failure to meet obligations related to share issuance or transfer agent requirements constitutes an Event of Default.

Risks

Potential for significant future dilution if the note is converted at a discounted price.
The company faces substantial financial penalties (150%-200% repayment) if an Event of Default occurs.
Restrictive covenants limit the company's operational and financial flexibility.
The company's ability to maintain its stock listing and comply with Exchange Act reporting requirements is critical, as failure constitutes an Event of Default.
The company must maintain sufficient authorized shares for conversion; failure to do so is an Event of Default.
The note is subject to various conditions that, if not met, can trigger an Event of Default, including issues with the transfer agent or trading market designations.
The company is prohibited from certain transactions like Section 3(a)(9) or 3(a)(10) offerings without incurring a significant liquidated damages charge.

Future Outlook

The company has entered into a financing agreement that provides immediate capital. The terms of the convertible note, including potential conversion and default provisions, will significantly influence future financial obligations and equity structure. The company must manage its operations to avoid default events and potential dilution.

Industry Context

StockSavvy.ai notes that this type of convertible note financing is common for early-stage or growth-oriented companies seeking capital without immediate equity dilution, but it carries inherent risks related to future dilution and default penalties. The terms suggest a company potentially facing capital constraints or seeking aggressive growth.

Comparison to Industry Standards

The 10% original issue discount and 12% one-time interest charge are within the typical range for high-risk convertible debt, though on the higher end.
The conversion discount of 25% (75% of the lowest trading price) is aggressive and common in distressed or growth financing, leading to significant potential dilution.
The default provisions, including a 150%-200% repayment multiplier, are punitive and indicative of a high-risk financing arrangement, often seen when lenders perceive a substantial risk of non-payment or default.
The 4.99% beneficial ownership limitation is a standard anti-takeover/dilution protection for the holder.
The inclusion of origination shares is a common practice to compensate the lender for the risk undertaken.

Corporate Governance

Change Type	Description	Effective Date	Impact Assessment
Restriction on Dividends and Distributions	Company cannot pay, declare, or set apart for payment any dividend or other distribution on capital stock, other than stock dividends in the form of additional common stock, without the Buyer's written consent.	Ongoing	Limits shareholder returns and flexibility in capital allocation.
Restriction on Stock Repurchases	Company cannot redeem, repurchase, or otherwise acquire any shares of capital stock without the Buyer's written consent.	Ongoing	Prevents the company from engaging in share buyback programs, which could otherwise support share price or return capital to shareholders.
Restriction on Asset Sales	Company cannot sell, lease, or otherwise dispose of any significant portion of its assets outside the ordinary course of business without the Buyer's written consent.	Ongoing	Limits strategic flexibility regarding asset management and potential divestitures.
Restriction on Loans and Advances	Company cannot lend money, give credit, or make advances to any person (including officers, directors, employees, subsidiaries, and affiliates) without the Buyer's written consent, except for pre-existing commitments, ordinary course of business, or amounts not exceeding $50,000.	Ongoing	Restricts internal financing and employee/affiliate transactions.
Prohibition on Section 3(a)(9) or 3(a)(10) Transactions	Company cannot enter into transactions structured under Section 3(a)(9) or 3(a)(10) of the 1933 Act without incurring a 25% liquidated damages charge.	Ongoing	Limits the company's ability to utilize certain common registration exemptions for future offerings.

Stakeholder Impact

Shareholders: Potential for significant dilution due to the low conversion price and the issuance of origination shares. Restrictions on dividends and repurchases limit potential returns.
Creditors: The company's ability to service existing and future debt may be impacted by the covenants and potential default scenarios related to this note.
Management: Subject to increased scrutiny and potential limitations on decision-making due to covenants requiring the buyer's consent for significant actions.

Next Steps

Picard Medical must make monthly amortization payments starting July 1, 2026.
The company must comply with all covenants and obligations outlined in the Note and Purchase Agreement.
The company must manage its operations to avoid any Event of Default.
The company may need to solicit stockholder consent for certain actions, such as exceeding 19.99% stock issuance limits.
The company must maintain sufficient authorized shares for potential note conversions.

Key Dates

Date	Description
2026-04-07	Issue Date of the Convertible Promissory Note and Execution Date of the Securities Purchase Agreement.
2026-07-01	First monthly amortization payment due.
2026-12-01	Last monthly amortization payment due, which is also the Maturity Date of the Note.

Recommendation

hold

While the financing provides necessary capital, the terms are highly unfavorable, including a significant discount, punitive default clauses, and substantial future dilution potential. Existing shareholders should monitor the company's ability to manage these obligations and avoid default. New investors should be aware of the high-risk nature of this financing.

Keywords

convertible promissory note, securities purchase agreement, Quick Capital, LLC, Picard Medical, Inc., financing, equity, dilution, event of default

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.